Mark W Hahn
CIK 1408502 · Chief Financial Officer · last filed 2026-05-18
Mark W Hahn is a Chief Financial Officer who has filed 59 SEC Form 4 insider transactions across 4 companies since 2012. The most recent filing, for SLNO, was dated May 18, 2026. Across all open-market trades the lifetime net is −$35.1M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
4
59
-$35.05M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SLNO | Director | 0 | $53.01 | $0 | $0 | 2 | 2026-05-18 |
| Verona Pharma plc (VRNA) Delisted | Chief Financial Officer | 3,285,280 | $106.91 | $351.23M | -$35.03M | 42 | 2025-10-08 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | Chief Financial Officer | 0 | — | — | -$27.9K | 7 | 2019-11-12 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | EVP and CFO | — | — | — | $0 | 7 | 2017-02-27 |
Recent Filings
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-18 | SLNO | Disp (D) | −10,046 | $0 | EDGAR |
| 2025-10-14 | SLNO | Grant (A) | +10,046 | $0 | EDGAR |
| 2025-10-08 | Verona Pharma plc (VRNA) Delisted | Mixed | −11,264,968 | $0 | EDGAR |
| 2025-09-03 | Verona Pharma plc (VRNA) Delisted | Gift (G) | −1,200,000 | $0 | EDGAR |
| 2025-08-05 | Verona Pharma plc (VRNA) Delisted | Mixed | +46,784 | -$2.75M | EDGAR |
| 2025-07-09 | Verona Pharma plc (VRNA) Delisted | Mixed | +139,192 | -$1.03M | EDGAR |
| 2025-06-13 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −400,000 | -$4.56M | EDGAR |
| 2025-05-29 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −400,000 | -$3.73M | EDGAR |
| 2025-05-05 | Verona Pharma plc (VRNA) Delisted | Mixed | −387,008 | -$5.31M | EDGAR |
| 2025-05-01 | Verona Pharma plc (VRNA) Delisted | Mixed | +139,152 | -$811.4K | EDGAR |